Scopus
YÖKSİS Eşleşti
Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
Rheumatology International · Mart 2023
YÖKSİS Kayıtları
Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
Springer Science and Business Media LLC - Rheumatology International · 2022 SCI-Expanded
DOÇENT KEMAL EROL →
Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
Rheumatology International · 2023 SCI-Expanded
DOÇENT ELİF BALEVİ BATUR →
Makale Bilgileri
DergiRheumatology International
Yayın TarihiMart 2023
Cilt / Sayfa43 · 523-531
Scopus ID2-s2.0-85137505422
Özet
To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements.
Yazarlar (35)
1
Erhan Capkin
ORCID: 0000-0003-2728-5934
2
Ali Yazıcı
ORCID: 0000-0002-5875-5524
3
Murat Karkucak
ORCID: 0000-0002-4348-8398
4
Yunus Durmaz
ORCID: 0000-0002-1727-0088
5
Murat Toprak
ORCID: 0000-0002-6490-4645
6
Şebnem Ataman
ORCID: 0000-0003-3570-3825
7
Nilay Şahin
ORCID: 0000-0001-6062-6935
8
Nihan Cüzdan
ORCID: 0000-0001-7238-657X
9
Meliha Kasapoğlu Aksoy
ORCID: 0000-0003-4688-0464
10
Mustafa Erkut Önder
ORCID: 0000-0001-9349-9530
11
Münevver Serdaroglu Beyazal
ORCID: 0000-0001-5903-5708
12
Nilgün Mesci
ORCID: 0000-0002-8925-8301
13
Merve Baykul
ORCID: 0000-0003-0434-396X
14
Meltem Alkan Melikoğlu
ORCID: 0000-0001-7519-9470
15
Hakan Alkan
ORCID: 0000-0001-8461-9131
16
Deniz Dulgeroglu
ORCID: 0000-0001-7513-6007
17
Ahmet Kıvanç Cengiz
ORCID: 0000-0002-4390-7169
18
Kemal Nas
ORCID: 0000-0002-5845-0851
19
Elif Balevi Batur
ORCID: 0000-0001-8886-1144
20
Aslı Çalışkan Uçkun
ORCID: 0000-0002-2492-4852
21
Hülya Deveci
ORCID: 0000-0001-7491-1569
22
Kemal Erol
ORCID: 0000-0003-0673-3961
23
Ilknur Albayrak Gezer
24
Gürkan Akgöl
ORCID: 0000-0003-1948-6410
25
Mehmet Tuncay Duruöz
ORCID: 0000-0003-3584-2788
26
Okan Küçükakkaş
ORCID: 0000-0001-6971-4229
27
Selda Sarıkaya
ORCID: 0000-0002-8015-0513
28
Aylin Rezvani
ORCID: 0000-0002-5852-3854
29
Tuğba Atan
ORCID: 0000-0003-1229-8679
30
Feride Göğüş
ORCID: 0000-0003-0921-5991
31
Gökhan Çağlayan
ORCID: 0000-0003-4630-5849
32
Yaşar Keskin
ORCID: 0000-0003-4457-5917
33
Ayşe Selcen Bulut Keskin
ORCID: 0000-0001-5724-467X
34
Nuran Öz
ORCID: 0000-0002-1002-962X
35
Gürdal Yılmaz
ORCID: 0000-0002-5967-9615
Anahtar Kelimeler
Biologic agents
Hepatitis
Inflammatory arthritis
Viral reactivation
Kurumlar
Aksaray Üniversitesi
Aksaray Turkey
Ankara Numune Education and Research Hospital
Ankara Turkey
Ankara Üniversitesi
Ankara Turkey
Atatürk Üniversitesi
Erzurum Turkey
Balikesir Üniversitesi
Balikesir Turkey
Balıkesir Atatürk City Hospital
Balikesir Turkey
Bezmialem Foundation University
Istanbul Türkiye
Bülent Ecevit University
Zonguldak Turkey
Bursa Yüksek lhtisas Training and Research Hospital
Bursa Turkey
Çanakkale Onsekiz Mart Üniversitesi
Canakkale Turkey
Cumhuriyet Üniversitesi Tip Fakültesi
Sivas Turkey
Firat Üniversitesi Tip Fakültesi
Elazig Turkey
Gazi University, Faculty of Medicine
Ankara Turkey
Haydarpasa Numune Egitim ve Arastýrma Hastanesi
Istanbul Turkey
Hitit University
Corum Turkey
İstanbul Medipol Üniversitesi
Istanbul Turkey
Karabük Training and Research Hospital
Karabuk Turkey
Karadeniz Technical University
Trabzon Turkey
Kayseri City Hospital
Kayseri Türkiye
Marmara Üniversitesi Tip Fakültesi
Istanbul Turkey
Ondokuz Mayis Üniversitesi
Samsun Turkey
Pamukkale Üniversitesi Tip Fakültesi
Denizli Turkey
Recep Tayyip Erdogan University
Rize Turkey
Sakarya Üniversitesi
Serdivan Turkey
Selçuk Tip Fakültesi
Konya Turkey
T. C. Sağlık Bakanlığı Ankara Diskapi Yildirim Beyazit Eğitim ve Araştirma Hastanesi
Ankara Turkey
Tokat Gaziosmanpaşa Üniversitesi
Tokat Turkey
Van Yüzüncü Yıl Üniversitesi
Van Turkey
Metrikler
3
Atıf
35
Yazar
4
Anahtar Kelime